- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
NSCLC treatment market value to approach $11 billion by 2021
8 September 2015 • Author: Victoria White
The global market value for Non-Small Cell Lung Cancer (NSCLC) treatment will rise from $6.9 billion in 2014 to $10.9 billion by 2021, representing a Compound Annual Growth Rate (CAGR) of 8.5%, says business intelligence provider GBI Research.
The Company’s latest report, Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 – Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line, states that this increase will occur across the eight major markets of the US, Canada, UK, Germany, France, Italy, Spain and Japan, driven primarily by the introduction of novel immune-checkpoint inhibitors, such as Opdivo and Keytruda, during the forecast period.
These new therapies will capture a significant share of the second-line treatment space. As well as strong clinical performances commanding premium pricing, they are expected to increase the degree of segmentation in the NSCLC therapeutics market and add further complexity to the treatment algorithm.
Joshua Libberton, Senior Analyst for GBI Research, said, “The majority of new drugs will target the second-line treatment of NSCLC in both squamous and non-squamous patient subsets, leading to a crowded treatment algorithm for these patient populations.
“Ultimately, due to their strong clinical performances, immunotherapies will have a greater uptake than other second-line market entrants, such as Custirsen and Rociletinib.”
Market share of generic NSCLC therapeutics will slowly decline by 2021
The analyst adds that the NSCLC therapeutics market will also see the launches of two first-line treatments for squamous cell patients during the forecast period, namely Necitumumab, which is due to launch in early 2016, and Yervoy (ipilimumab) in 2017.
Libberton continued, “The squamous patient subset is currently very limited in terms of first-line treatment options, meaning these new drugs will be important for driving market growth and improving patient outlook.
“While generic chemotherapies will remain an integral aspect of NSCLC treatment, with platinum-based regimens being crucial in the first-line setting for all patients and docetaxel being a key therapy for second-line patients, their market share will slowly decline by 2021 as new premium, targeted therapies enter the arena.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Butterworth Laboratories Ltd CAPSUGEL NV Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) Eurofins BioPharma Product Testing EUROGENTEC F.P.S. Food and Pharma Systems Srl GE Analytical Instruments IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited MA Business Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Ocean Optics Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Viavi Solutions, Inc Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics